



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



ARQ 531

Item No. 30165

CAS Registry No.: 2095393-15-8
Formal Name: 1,5-anhydro-2-[[5-(2-chloro-4-phenoxybenzoyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-2,3,4-trideoxy-D-erythro-hexitol

Synonyms: MK-1026, Nemtabutrinib

MF: C₂₅H₂₃ClN₄O₄


FW: 478.9

Purity: ≥98%

Supplied as: A solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

ARQ 531 is supplied as a solid. A stock solution may be made by dissolving the ARQ 531 in the solvent of choice, which should be purged with an inert gas. ARQ 531 is soluble in methanol and DMSO.

Description

ARQ 531 is an inhibitor of Bruton's tyrosine kinase (BTK; IC₅₀ = 0.85 nM).¹ It reduces the viability of, and inhibits BTK autophosphorylation in, OCI-AML-2 acute myeloid leukemia (AML) cells when used at concentrations of 0.3 and 1 μM.² *In vivo*, ARQ 531 (75 mg/kg) reduces tumor growth in an SU-DHL-4 B cell lymphoma mouse xenograft model.¹

References

1. Eathiraj, S., Yu, Y., Savage, R., *et al.* Abstract 1963: ARQ 531, a potent reversible BTK inhibitor, exhibits potent antitumor activity in ibrutinib-resistant diffuse large B-cell lymphoma. *Cancer Res.* **78(13 Suppl)**, 1963 (2018).
2. Soncini, D., Orecchioni, S., Ruberti, S., *et al.* The new small tyrosine kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs. *Haematologica* **105(10)**, 2420-2431 (2020).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/29/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM